Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX".

Journal of the American Academy of Dermatology·2026

Same author

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.

Dermatology and therapy·2025

Same author

Using targeted therapies for inflammatory dermatoses.

Seminars in cutaneous medicine and surgery·2018

Same author

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.

American journal of clinical dermatology·2018

Same author

Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.

Acta dermato-venereologica·2016

Same author

The role of TNF inhibitors in psoriatic disease.

Seminars in cutaneous medicine and surgery·2014

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Update on TNF Inhibitors in Dermatology.

Jeffrey M Sobell¹

¹Assistant Professor of Dermatology Tufts University School of Medicine Director, Psoriasis Treatment Center SkinCare Physicians Chestnut Hill, Massachusetts.

Seminars in Cutaneous Medicine and Surgery

|August 19, 2016

Summary

This summary is machine-generated.

New tumor necrosis factor (TNF) inhibitors show promise for pediatric psoriasis and hidradenitis suppurativa. Upcoming biosimilar TNF agents require rigorous testing for US approval, offering new therapeutic options.

Keywords:

Biosimilars TNF inhibitors hidradenitis suppurativa pediatric psoriasis psoriasis

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Experiment Videos

Last Updated: Mar 16, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Area of Science:

Dermatology
Immunology
Pharmacology

Background:

Emerging data suggest novel dermatological applications for tumor necrosis factor (TNF) inhibitors.
Conditions such as pediatric psoriasis and hidradenitis suppurativa are being explored for new treatment indications.

Purpose of the Study:

To review potential new indications for TNF inhibitors in dermatology.
To discuss the development and approval process for biosimilar TNF agents.

Main Methods:

Review of emerging scientific data and clinical trial information.
Analysis of regulatory requirements for biosimilar drug approval.

Main Results:

TNF inhibitors are being investigated for pediatric psoriasis and hidradenitis suppurativa.
New biosimilar TNF agents are nearing completion of development and regulatory review.

Conclusions:

Biosimilar TNF inhibitors represent a significant advancement in dermatological treatment options.
Rigorous testing, including analytic, toxicity, pharmacokinetic, pharmacodynamic, and clinical studies, is essential for the approval of biosimilar agents.